Moody Aldrich Partners LLC Buys New Position in Mirati Therapeutics Inc (MRTX)

Moody Aldrich Partners LLC bought a new position in shares of Mirati Therapeutics Inc (NASDAQ:MRTX) in the first quarter, Holdings Channel reports. The fund bought 13,141 shares of the biotechnology company’s stock, valued at approximately $963,000.

Several other hedge funds have also recently modified their holdings of the stock. FMR LLC boosted its stake in Mirati Therapeutics by 3.0% in the fourth quarter. FMR LLC now owns 2,196,388 shares of the biotechnology company’s stock valued at $93,171,000 after acquiring an additional 63,699 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Mirati Therapeutics by 30.0% in the fourth quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock valued at $87,086,000 after buying an additional 474,097 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Mirati Therapeutics by 88.6% in the first quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock valued at $149,147,000 after buying an additional 956,022 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Mirati Therapeutics by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,431,905 shares of the biotechnology company’s stock valued at $67,443,000 after buying an additional 26,316 shares during the last quarter. Finally, Vanguard Group Inc raised its holdings in shares of Mirati Therapeutics by 1.9% in the third quarter. Vanguard Group Inc now owns 1,431,905 shares of the biotechnology company’s stock valued at $67,443,000 after buying an additional 26,316 shares during the last quarter.

A number of equities research analysts have recently commented on the stock. BidaskClub raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research cut shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $66.00 target price on shares of Mirati Therapeutics in a report on Wednesday, May 1st. JPMorgan Chase & Co. assumed coverage on shares of Mirati Therapeutics in a report on Wednesday, April 17th. They issued a “neutral” rating and a $72.00 target price for the company. Finally, Credit Suisse Group assumed coverage on shares of Mirati Therapeutics in a report on Monday, March 25th. They issued an “outperform” rating and a $85.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $69.08.

In related news, major shareholder Venbio Select Advisor Llc sold 23,781 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $72.80, for a total transaction of $1,731,256.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher C. Lemasters sold 60,000 shares of the stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $71.77, for a total transaction of $4,306,200.00. Following the transaction, the executive vice president now directly owns 60,000 shares of the company’s stock, valued at $4,306,200. The disclosure for this sale can be found here. Insiders have sold 1,382,911 shares of company stock valued at $99,772,950 over the last three months. 4.86% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:MRTX traded down $0.27 on Friday, reaching $67.23. The company’s stock had a trading volume of 1,235 shares, compared to its average volume of 648,111. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of -21.07 and a beta of 1.95. Mirati Therapeutics Inc has a 52-week low of $28.50 and a 52-week high of $80.00.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.20). The company had revenue of $1.24 million for the quarter. On average, equities research analysts forecast that Mirati Therapeutics Inc will post -5 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Moody Aldrich Partners LLC Buys New Position in Mirati Therapeutics Inc (MRTX)” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/10/moody-aldrich-partners-llc-buys-new-position-in-mirati-therapeutics-inc-mrtx.html.

Mirati Therapeutics Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Read More: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.